Gremse-IT
Gremse-IT provides GPU-accelerated, multimodal preclinical biomedical image analysis software (Imalytics Preclinical), serving academic imaging cores, pharmaceutical/biotech R&D groups (radiopharmaceuticals, theranostics), CROs, and medical device manufacturers across 200+ institutions globally.
- Company typePrivate
- Founded2016
- HeadquartersAachen, Germany
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Gremse-IT does
Gremse-IT GmbH is a privately held, founder-led software company headquartered in Aachen, Germany, with additional offices in Montreal, Canada and Yangzhou, China. Founded in 2016, the company has 11–50 employees and is focused exclusively on preclinical biomedical image analysis, serving academic imaging cores, pharmaceutical and biotech R&D teams (notably in radiopharmaceuticals and theranostics), contract research organizations, and medical device manufacturers. Its commercial traction includes deployments in 200+ institutions globally, with named customers spanning University of Missouri, University of Wisconsin, UCLA, Washington University in St. Louis, Cologne University Hospital, RayzeBio, and Charles River/Inotiv.
The company's flagship product, Imalytics Preclinical, is a GPU-accelerated, multimodal image analysis platform that supports PET, SPECT, CT, MRI, ultrasound, and optical imaging in a single workspace, with AI-assisted organ segmentation, batch processing, and pharmacokinetic/dosimetry modeling. A proprietary GFF (Grace File Format) underpins data storage with lossless compression and cryptographic hashing, and an open-source Python package (gffio) extends the platform into external ML workflows. Imalytics is compatible with 30+ preclinical imaging vendors including Bruker, Siemens, Mediso, Revvity, and SCANCO, creating broad install-base reach.
Gremse-IT monetizes through quote-based software licensing (both perpetual and time-limited subscription models with separable support contracts), complemented by three services: an AI-powered Radiopharmaceutical Biodistribution Pipeline add-on, Image Analysis as a Service (expert-reviewed quantification), and OEM Software Development for device manufacturers. Distribution is direct, via field sales, with free demos and a consultation-based sales motion targeting enterprise and institutional buyers worldwide.
Gremse-IT firmographics
Firmographics- Name
- Gremse-IT
- Legal name
- Gremse-IT GmbH
- Website
- https://gremse-it.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Gremse-IT provides GPU-accelerated, multimodal preclinical biomedical image analysis software (Imalytics Preclinical), serving academic imaging cores, pharmaceutical/biotech R&D groups (radiopharmaceuticals, theranostics), CROs, and medical device manufacturers across 200+ institutions globally.
- Ownership category
- akta.pro rank
Gremse-IT industry classification
Industry- Product category
- Preclinical Imaging Software
- NAICS
- Software Publishers (513210), Computer Systems Design and Related Services (54151)
- SIC
- Services-Prepackaged Software (7372), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)
- akta.pro secondary industries
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Gremse-IT is headquartered
LocationHeadquarters
- HQ city
- Aachen
- HQ country
- Germany
- HQ region
- Europe
Offices3 records
Markets served
Gremse-IT business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Software Licensing: Imalytics Preclinical is sold as licensed software with two primary models: (1) Permanent license with limited support period, and (2) Time-limited license with support included for the contract duration. The software runs locally on Windows or MacOS systems and requires hardware-specific license activation. Additional support contracts can be purchased separately for ongoing technical assistance.
- Professional Services: Custom AI-powered biodistribution pipelines, quantitative image analysis as a service, and tailored software development for CROs, pharmaceutical companies, and device manufacturers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | Permanent License |
| Subscription | Multi-year contract | Time-Limited License |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Gremse-IT product offering
Product offeringCore offering
Gremse-IT develops and sells Imalytics Preclinical, a GPU-accelerated software platform for visualization, segmentation, and quantification of preclinical biomedical imaging data across PET, SPECT, CT, MRI, ultrasound, and optical modalities. The company complements the software with an AI-powered Radiopharmaceutical Biodistribution Pipeline, Image Analysis as a Service, and OEM/custom software development for device manufacturers and CROs.
Product overview
Gremse-IT offers a unified product ecosystem centered on the Imalytics Preclinical platform for preclinical biomedical image analysis. The core platform supports multimodal imaging (PET, SPECT, CT, MRI, ultrasound, and optical) with GPU acceleration, AI-assisted segmentation, and batch processing capabilities. Three complementary service offerings surround the platform: the AI-powered Radiopharmaceutical Biodistribution Pipeline for automated organ segmentation and dosimetry; Image Analysis as a Service for expert-reviewed quantification; and OEM Software Development for tailored imaging solutions. An open-source Python extension (gffio) enables Python users to integrate Imalytics data into custom preprocessing workflows. The product portfolio serves over 200 institutions and pharmaceutical companies worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- Imalytics Preclinical: Flagship image analysis platform for preclinical biomedical imaging supporting PET, SPECT, CT, MRI, ultrasound, and optical imaging modalities with GPU-accelerated performance and AI-assisted segmentation.
- gffio
Products and services
- Imalytics Preclinical
Quantifiable outcome
- Analysis time reduced from days to minutes with AI-powered biodistribution pipeline
- +3 more outcomes
Companies that use Gremse-IT
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles4 records
Gremse-IT technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature8 records
Gremse-IT partnerships and signals
Strategic signalScale indicators2 records
Recent moves6 records
Expansion highlights5 records
Gremse-IT competitors and assessment
Company assessmentBroad incumbents
- Revvity (formerly PerkinElmer): Revvity offers the VivoQuant preclinical imaging analysis platform alongside its IVIS optical imaging systems and other molecular imaging modalities. It is a broad incumbent serving similar pharma/biotech and academic preclinical imaging customers with bundled hardware-plus-software offerings, competing head-to-head with Imalytics in PET, SPECT, CT, and optical workflows.
- Siemens Healthineers: Siemens offers syngo.via and other imaging software platforms predominantly for clinical but also for preclinical research workflows. It competes as a broad incumbent with strong OEM bundling, particularly in PET/CT and SPECT where Imalytics has strong academic and pharma penetration.
- Mediso Medical Imaging Systems: Mediso manufactures preclinical PET/SPECT/CT scanners and supplies associated software for image reconstruction and quantification. It is both a compatible hardware partner for Imalytics and a competitor via its bundled analysis tools in multimodal preclinical imaging.
- Thermo Fisher Scientific (Amira/Avizo): Thermo Fisher's Amira/Avizo 3D visualization and analysis software is widely used in life sciences imaging, including preclinical applications. While broader in scope (materials science, clinical), it overlaps with Imalytics's 3D/4D visualization and segmentation workflows for biomedical researchers.
- Bruker: Bruker is a major preclinical imaging OEM whose ParaVision software is bundled with its MRI, PET, and microCT scanners. As both a partner (Imalytics is compatible with Bruker systems) and a competitor, Bruker represents the most significant bundled-software threat to Gremse-IT in academic and pharma preclinical imaging labs.
Emerging players
- Fiji / ImageJ: Fiji (and its ImageJ base) is the de facto open-source standard for biomedical image analysis in academic labs. While narrower in nuclear imaging quantification, it remains a baseline competitor for many academic preclinical imaging cores considering Imalytics Preclinical.
- 3D Slicer: 3D Slicer is a widely used open-source platform for 3D medical image visualization, segmentation, and analysis with growing preclinical adoption and an active extension ecosystem. It is a partial substitute that competes most aggressively on price-sensitive academic deals, particularly for MRI/CT workflows.
Direct peers
- Visian Medical Imaging: Visian provides preclinical image analysis software and services similar in scope to Imalytics Preclinical, with a focus on multimodal PET, SPECT, CT, and MRI quantification. It targets the same academic imaging core and pharma/CRO buyers with comparable feature sets.
- PMOD Technologies: PMOD provides specialized software for quantitative PET/SPECT data analysis, kinetic modeling, and dosimetry in preclinical and clinical imaging. It directly overlaps with Imalytics Preclinical's nuclear imaging quantification, Patlak/compartmental modeling, and voxel dosimetry capabilities, serving the same pharma and academic research buyer.
- inviCRO (iPRECIO / Molecular Imaging): inviCRO (now part of Capsule Pharma) provides preclinical and translational imaging analysis software and services to pharma and biotech, overlapping directly with Imalytics's biodistribution, dosimetry, and quantitative imaging offerings for drug development customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Gremse-IT social profiles
Digital presenceGremse-IT financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gremse-IT leadership team
Management profileNumber of profiles
Profiles1 record
Gremse-IT funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gremse-IT M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gremse-IT
What does Gremse-IT do?
Gremse-IT develops and sells Imalytics Preclinical, a GPU-accelerated software platform for visualization, segmentation, and quantification of preclinical biomedical imaging data across PET, SPECT, CT, MRI, ultrasound, and optical modalities. The company complements the software with an AI-powered Radiopharmaceutical Biodistribution Pipeline, Image Analysis as a Service, and OEM/custom software development for device manufacturers and CROs.
Is Gremse-IT a public or private company?
Gremse-IT is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Gremse-IT founded?
Gremse-IT was founded in 2016. It employs 11 to 50 people.
Where is Gremse-IT based?
Gremse-IT is headquartered in Aachen, Germany, in the Europe region.
How does Gremse-IT make money?
Two revenue lines are on record. Software Licensing is the primary driver. The others are professional Services.
Who are Gremse-IT's main competitors?
Broad incumbents on record are Revvity (formerly PerkinElmer), Siemens Healthineers, Mediso Medical Imaging Systems, Thermo Fisher Scientific (Amira/Avizo) and Bruker. Emerging players are Fiji / ImageJ and 3D Slicer. Direct peers are Visian Medical Imaging, PMOD Technologies and inviCRO (iPRECIO / Molecular Imaging).
Does Gremse-IT have an API?
No public API is recorded for Gremse-IT.
What industry is Gremse-IT in?
Gremse-IT's product category is Preclinical Imaging Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 513210 and its SIC code is 7372.